OsamaRahmaMD

PubMed

• Efficacy, safety, and biomarker analyses of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with advanced non-small cell lung can...
  Arun Rajan, Houssein Abdul Sater, Osama Rahma, Richy Agajanian, Wiem Lassoued, Jennifer L Marté, Yo-Ting Tsai, Renee N Donahue, Elizabeth Lamping, Shania Bailey, Andre...> ;Journal for Immunotherapy of Cancer. 2024 Mar 13
• PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with Pancreatic Cancer.
  Ali, L., Lenehan, P., Cardot-Ruffino, V., Dias Costa, A., Katz, M., Bauer, T., Nowak, J., Wolpin, B., Abrams, T., Patel, A., Clancy, T., Wang, J., Mancias, J., Reilley...> ;Clinical Cancer Research. 2024 Feb 1
• Ziv-aflibercept plus pembrolizumab in patients with advanced melanoma resistant to anti-PD-1 treatment.
  Baginska, J., Nau, A., Gomez Diaz, I., Giobbie-Hurder, A., Weirather, J., Vergara, J., Abrecht, C., Hallisey, M., Dennis, J., Severgnini, M., Huezo, J., Marciello, I.,...> ;Cancer Immunology, Immunotherapy. 2024 Jan 18
• 2 citations
  Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in patients with resectable or borderline resectabl...
  Matthew H G Katz, Gina R Petroni, Todd Bauer, Matthew J Reilley, Brian M Wolpin, Chee-Chee Stucky, Tanios S Bekaii-Saab, Rawad Elias, Nipun Merchant, Andressa Dias Cos...> ;Journal for Immunotherapy of Cancer. 2023 Dec 1
• The Cholangiocarcinoma in the Young (CITY) Study: Tumor Biology, Treatment Patterns, and Survival Outcomes in Adolescent Young Adults With Cholangiocarcinoma.
  Leontios Pappas, Islam Baiev, Stephanie Reyes, Andrea Grace Bocobo, Apurva Jain, Kristen Spencer, Tri Minh Le, Osama E Rahma, Jordan Maurer, Jen Stanton, Karen Zhang, ...> ;JCO Precision Oncology. 2023 Aug 1
• 3 citations
  Prospective Correlation of Magnetic Resonance Tumor Regression Grade With Pathologic Outcomes in Total Neoadjuvant Therapy for Rectal Adenocarcinoma.
  William A Hall, Jiahe Li, Y Nancy You, Marc J Gollub, Joseph R Grajo, Mark Rosen, Greg dePrisco, Greg Yothers, Jennifer A Dorth, Osama E Rahma, Marcia M Russell, Howar...> ;Journal of Clinical Oncology. 2023 Oct 10
• 1 citations
  Profiling of Natural Killer Interactions With Cancer Cells Using Mass Cytometry.
  Margaret Hallisey, Jenna Dennis, Elizabeth P Gabriel, Alyssa Masciarelli, Jiajia Chen, Charlotte Abrecht, Martha Brainard, William M Marcotte, Han Dong, Emma Hathaway,...> ;Laboratory Investigation; a Journal of Technical Methods and Pathology. 2023 Aug 1
• 3 citations
  Molecular profiling and treatment pattern differences between intrahepatic and extrahepatic cholangiocarcinoma.
  Kristen Spencer, Leontios Pappas, Islam Baiev, Jordan Maurer, Andrea Grace Bocobo, Karen Zhang, Apurva Jain, Anaemy Danner De Armas, Stephanie Reyes, Tri Minh Le, Osam...> ;Journal of the National Cancer Institute. 2023 Jul 6
• 4 citations
  First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1).
  Sophie Postel-Vinay, Vincent K Lam, Willeke Ros, Todd M Bauer, Aaron R Hansen, Daniel C Cho, F Stephen Hodi, Jan H M Schellens, Jennifer K Litton, Sandrine Aspeslagh, ...> ;Journal for Immunotherapy of Cancer. 2023 Mar 1
• 2 citations
  Programmatic Precision Oncology Decision Support for Patients With Gastrointestinal Cancer.
  Rachel B Keller, Tali Mazor, Lynette Sholl, Andrew J Aguirre, Harshabad Singh, Nilay Sethi, Adam Bass, Ankur K Nagaraja, Lauren K Brais, Emma Hill, Connor Hennessey, M...> ;JCO Precision Oncology. 2023 Jan 1
• Safety and effectiveness of combination versus monotherapy with immune checkpoint inhibitors in patients with preexisting autoimmune diseases.
  Pankti Reid, Sabina Sandigursky, Juhee Song, Maria A Lopez-Olivo, Houssein Safa, Samuel Cytryn, Elizaveta Efuni, Maryam Buni, Anna Pavlick, Michelle Krogsgaard, Osama ...> ;Oncoimmunology. 2023 Jan 1
• 20 citations
  Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors.
  Rachel E Sanborn, Michael J Pishvaian, Margaret K Callahan, Amy Weise, Branimir I Sikic, Osama Rahma, Daniel C Cho, Naiyer A Rizvi, Mario Sznol, Jose Lutzky, Julie E B...> ;Journal for Immunotherapy of Cancer. 2022 Aug 1
• 1 citations
  Multiple high-grade and rare immune-related adverse events in a colon cancer patient with genomic and cytokine profiling.
  Kevin Tyan, Osama Abu-Shawer, Joanna Baginska, Mariano Severgnini, Michael Manos, Henrikas Vaitkevicius, Shilpa Grover, F Stephen Hodi, Osama E Rahma> ;Immunotherapy. 2022 Aug 1
• 91 citations
  Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial.
  Lacey J Padrón, Deena M Maurer, Mark H O'Hara, Eileen M O'Reilly, Robert A Wolff, Zev A Wainberg, Andrew H Ko, George Fisher, Osama Rahma, Jaclyn P Lyman, Christopher ...> ;Nature Medicine. 2022 Jun 1
• 15 citations
  First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of Response.
  Timothy A Yap, Justin F Gainor, Margaret K Callahan, Gerald S Falchook, Russell K Pachynski, Patricia LoRusso, Shivaani Kummar, Geoffrey T Gibney, Howard A Burris, Sco...> ;Clinical Cancer Research. 2022 Sep 1
• 53 citations
  Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial.
  Charu Aggarwal, Amy Prawira, Scott Antonia, Osama Rahma, Anthony Tolcher, Roger B Cohen, Yanyan Lou, Ralph Hauke, Nicholas Vogelzang, Dan P Zandberg, Arash Rezazadeh K...> ;Journal for Immunotherapy of Cancer. 2022 Apr 1
• 11 citations
  Phase IB study of ziv-aflibercept plus pembrolizumab in patients with advanced solid tumors.
  Osama E Rahma, Kevin Tyan, Anita Giobbie-Hurder, Andrew S Brohl, Philippe L Bedard, Daniel J Renouf, Elad Sharon, Howard Streicher, Emma Hathaway, Rachel Cunningham, M...> ;Journal for Immunotherapy of Cancer. 2022 Mar 1
• 2 citations
  Durable clinical benefit from PARP inhibition in a platinum-sensitive, BRCA2-mutated pancreatic cancer patient after earlier progression on placebo treatment on the PO...
  Douglas Rubinson, Brian M Wolpin, Ilana S Warsofsky, David P Ryan, Kimberly Perez, Osama Rahma, Harshabad Singh, Matthew B Yurgelun, Geoffrey I Shapiro, Andrew J Aguir...> ;Journal of Gastrointestinal Oncology. 2021 Dec 1
• 9 citations
  Immune-related adverse events and kidney function decline in patients with genitourinary cancers treated with immune checkpoint inhibitors
  Harish Seethapathy, Sarah Street, Ian A. Strohbehn, Meghan Lee, Sophia H. Zhao, Nifasha Rusibamayila, Donald F. Chute, Xin Gao, M.D. Michaelson, Osama E. Rahma, Toni K...> ;European Journal of Cancer. 2021 Nov 1
• 27 citations
  Effect of corticosteroid dosing on outcomes in high-grade immune checkpoint inhibitor hepatitis.
  Michael Li, Danny Wong, Alexander S Vogel, Jordan Sack, Osama E. Rahma, F. Stephen Hodi, Stephen D. Zucker, Shilpa Grover> ;Hepatology. 2021 Oct 28
• 16 citations
  Utility of Liver Biopsy in Diagnosis and Management of High-grade Immune Checkpoint Inhibitor Hepatitis in Patients With Cancer.
  Michael Li, Jordan Sack, Phoenix Bell, Osama E. Rahma, Amitabh Srivastava, Shilpa Grover, Stephen D. Zucker> ;JAMA Oncology. 2021 Nov 1
• 1 citations
  Erratum: A randomized trial of combined PD-L1 and CTLA-4 inhibition with targeted low-dose or hypofractionated radiation for patients with metastatic colorectal cancer...
  Arta M. Monjazeb, Anita Giobbie-Hurder, Ana Lako, Emily M. Thrash, Ryan C. Brennick, Katrina Z. Kao, Claire Manuszak, Ryan D. Gentzler, Anteneh Tesfaye, Salma K. Jabbo...> ;Clinical Cancer Research. 2021 Sep 1
• 16 citations
  Predictors of rheumatic immune-related adverse events and de novo inflammatory arthritis after immune checkpoint inhibitor treatment for cancer
  Amy Cunningham-Bussel, Jiaqi Wang, Lauren C. Prisco, Lily W Martin, Kathleen M M Vanni, Alessandra Zaccardelli, Mazen Nasrallah, Lydia Gedmintas, Lindsey A MacFarlane,...> ;Arthritis & Rheumatology. 2021 Aug 16
• 2 citations
  Immune checkpoint inhibitor-induced thyroiditis is a risk factor for acute and chronic kidney dysfunction.
  Ian A. Strohbehn, Sarah Street, Donald F. Chute, Harish Seeethapathy, Meghan Lee, Rituvanthikaa Seethapathy, Zsofia D. Drobni, Osama E. Rahma, Tomas G. Neilan, Kerry L...> ;Nephrology, Dialysis, Transplantation. 2021 Aug 12
• 53 citations
  Early Use of High-Dose Glucocorticoid for the Management of irAE Is Associated with Poorer Survival in Patients with Advanced Melanoma Treated with Anti-PD-1 Monotherapy.
  Xue Bai, Jiani Hu, Allison Betof Warner, Henry T. Quach, Christopher G. Cann, Michael Z. Zhang, Lu Si, Bixia Tang, Chuanliang Cui, Xiaoling Yang, Xiaoting Wei, Lalit P...> ;Clinical Cancer Research. 2021 Aug 10
• Join now to see all

Lectures

• Phase Ib study to test the safety and activity of pembrolizumab (anti-PD-1) and trebananib (angiopoietin-2 inhibitor [Ang-2]) in patients with advanced solid tumors: U... 
  ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/25/2020
• Phase Ib study of pembrolizumab and trebananib (angiopoietin-2 inhibitor [Ang-2]): Preliminary analysis of the colorectal cancer (CRC) cohort. 
  2019 ASCO Annual Meeting - 6/1/2019